NCT00562380: AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma |
|
|
| Completed | 1 | 64 | US | ganitumab, laboratory biomarker analysis, pharmacological study, biopsy | Amgen, National Cancer Institute (NCI) | Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 04/10 | 06/10 | | |
